{"id":552885,"date":"2026-09-29T23:45:21","date_gmt":"2026-09-29T23:45:21","guid":{"rendered":"https:\/\/www.newjerseyheadlines.com\/news\/story\/552885\/sjogrens-syndrome-market-poised-for-sustained-growth-amid-advancements-in-treatment-and-clinical-innovation-by-2036-delveinsight-astellas-pharma-immunovant-sciences-nk-cells-artiva-biotherap.html"},"modified":"2026-09-29T23:45:21","modified_gmt":"2026-09-29T23:45:21","slug":"sjogrens-syndrome-market-poised-for-sustained-growth-amid-advancements-in-treatment-and-clinical-innovation-by-2036-delveinsight-astellas-pharma-immunovant-sciences-nk-cells-artiva-biotherap","status":"publish","type":"post","link":"http:\/\/www.northcarolinaheadlines.com\/news\/story\/552885\/sjogrens-syndrome-market-poised-for-sustained-growth-amid-advancements-in-treatment-and-clinical-innovation-by-2036-delveinsight-astellas-pharma-immunovant-sciences-nk-cells-artiva-biotherap.html","title":{"rendered":"Sjogren\u2019s Syndrome Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036 \u2013 DelveInsight | Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherap"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1790702394.jpg\" style=\"border:none !important\" target=\"_blank\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone size-medium wp-image-29\" title=\"Sjogren&rsquo;s Syndrome Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036 &ndash; DelveInsight | Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherap\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1790702394.jpg\" alt=\"Sjogren&rsquo;s Syndrome Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036 &ndash; DelveInsight | Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherap\" width=\"225\" height=\"119\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The Key Sjogren\u2019s syndrome Companies in the market include &#8211; Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherapeutics, Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici,  Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson &amp; Johnson, and others .<\/div>\n<p style=\"text-align: justify\"><strong>(Albany, New York) &#8211; September 29, 2026:<\/strong> DelveInsight&rsquo;s report <strong>&ldquo;Sjogren&rsquo;s Syndrome Market Insights, Epidemiology, and Market Forecast-2036,&rdquo;<\/strong> provides a comprehensive analysis of the Sjogren&rsquo;s Syndrome landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Get a Free sample for the Sjogren&rsquo;s syndrome Market Report: <\/strong><\/p>\n<p style=\"text-align: justify\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sjogrens-syndrome-market-size?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">https:\/\/www.delveinsight.com\/report-store\/sjogrens-syndrome-market-size<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Some of the key facts of the Sjogren&rsquo;s syndrome Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The Sj&ouml;gren&rsquo;s disease market size across the 7MM was valued at approximately <strong>USD 1 billion in 2025<\/strong> and is projected to reach nearly<strong> USD 10 billion by 2036<\/strong>, expanding at a <strong>CAGR of 26.2%<\/strong> during the forecast period from 2026 to 2036.<\/p>\n<\/li>\n<li>\n<p><strong>In September 2026, DDY391\/MRT-6160:<\/strong> Phase II Initiation: Novartis initiated the Phase II study of DDY391 in Sj&ouml;gren&rsquo;s disease, triggering a $50 million milestone payment to Monte Rosa Therapeutics.<\/p>\n<\/li>\n<li>\n<p><strong>In August 2026, Novartis&#8217;<\/strong> Phase III THALASSA study evaluating ianalumab in patients with high-symptom-burden Sj&ouml;gren&rsquo;s disease was listed as recruiting, with the study initiated in July 2026.<\/p>\n<\/li>\n<li>\n<p><strong>In July 2026, The Sj&ouml;gren&rsquo;s disease Phase IIa\/b study of DDY391<\/strong> was registered, evaluating the VAV1-directed molecular glue degrader for up to 52 weeks. The study is designed to assess efficacy, safety, tolerability, and dose response to support potential Phase III development.<\/p>\n<\/li>\n<li>\n<p><strong>In June 2026, Johnson &amp; Johnson<\/strong> reported new biomarker exploratory analyses from the Phase II DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe Sj&ouml;gren&#8217;s disease, a showing that participants with elevated autoantibody and immunoglobulin G (IgG) levels, who are often those who experience more substantial disease burden, showed greater clinical response rates.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2026,<\/strong> Researchers and sponsors continued to evaluate data from pivotal clinical studies of ianalumab and dazodalibep, while ongoing research efforts investigated novel therapeutic approaches targeting B-cell signaling, CD40-CD40L pathway interactions, and FcRn-mediated autoantibody mechanisms to address underlying disease processes.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2026, Novartis<\/strong> reported that ianalumab had received FDA Priority Review, while regulatory submissions had been completed in the US, Europe, and Japan, marking the transition of the program into global regulatory review.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2026,<\/strong> Enrollment and patient follow-up activities remained ongoing across multiple global Phase III clinical trials evaluating innovative immunomodulatory therapies for Sj&ouml;gren&rsquo;s syndrome, with efforts focused on lowering systemic disease burden and enhancing salivary and lacrimal gland function.<\/p>\n<\/li>\n<li>\n<p><strong>In February 2026, Amgen<\/strong> continued to advance dazodalibep through its Phase III clinical program, including the HZNP-DAZ-301 and HZNP-DAZ-303 trials, which are evaluating the therapy in patients with moderate-to-severe Sj&ouml;gren&rsquo;s syndrome. These studies are designed to assess the treatment&rsquo;s impact on systemic disease activity, symptom severity, and patient-reported clinical outcomes.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Novartis a<\/strong>nnounced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ianalumab for the treatment of Sj&ouml;gren&rsquo;s disease, the second most common rheumatic autoimmune disorder. Ianalumab is a fully human monoclonal antibody with a dual mechanism of action, targeting B-cells by both depleting them and inhibiting their activation and survival through BAFF-R blockade. Novartis intends to begin global regulatory submissions for ianalumab in early 2026. If approved, it would become the first targeted therapy for patients with Sj&ouml;gren&rsquo;s disease.<\/p>\n<\/li>\n<li>\n<p><strong>In December 2025, Amgen<\/strong> carried out a Phase 3 randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of dazodalibep in participants with Sj&ouml;gren&rsquo;s syndrome exhibiting moderate-to-severe systemic disease activity.<\/p>\n<\/li>\n<li>\n<p><strong>In December 2025, Novartis Pharmaceuticals<\/strong> announced a clinical study to evaluate the efficacy, safety, and tolerability of ianalumab (VAY736) in patients with active Sj&ouml;gren&rsquo;s syndrome. The study aims to assess the effects of monthly subcutaneous (s.c.) administration of ianalumab (VAY736) versus placebo in this patient population.<\/p>\n<\/li>\n<li>\n<p>In December 2025, Bristol Myers Squibb has initiated a Phase 3 clinical trial to evaluate the safety and efficacy of two dosing regimens of deucravacitinib in adult patients with active Sj&ouml;gren&rsquo;s syndrome.<\/p>\n<\/li>\n<li>\n<p>In August 2025, Novartis was seeking approval for its Sj&ouml;gren&rsquo;s disease therapy after positive results from two Phase III trials. The NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) studies evaluating ianalumab achieved their primary goal of reducing disease activity, as measured by the EULAR Sj&ouml;gren&rsquo;s Syndrome Disease Activity Index (ESSDAI) compared to placebo. The trials included 749 patients, with NEPTUNUS-1 assessing monthly intravenous ianalumab and NEPTUNUS-2 evaluating the safety and efficacy of subcutaneous ianalumab administered either monthly or every three months.<\/p>\n<\/li>\n<li>\n<p>In March 2025, Johnson &amp; Johnson announced that the US FDA has granted investigational nipocalimab Fast Track designation (FTD) for the treatment of adult patients with moderate-to-severe Sjogren&#8217;s disease, having previously been granted Breakthrough Therapy designation (BTD) for the investigational therapy late last year.<\/p>\n<\/li>\n<li>\n<p>In March 2025, Drawing on results from the Phase II DAHLIAS (NCT04968912) trial, the FDA has awarded Fast Track designation (FTD) to nipocalimab for the treatment of moderate-to-severe Sj&ouml;gren&rsquo;s disease. This marks the first Fast Track granted to an FcRn blocker for this condition and is expected to accelerate the development of the investigational therapy, which, if approved, would become the first FcRn blocker indicated for this autoantibody-driven disease.<\/p>\n<\/li>\n<li>\n<p>In March 2025, Johnson &amp; Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to its investigational therapy, nipocalimab, for treating adults with moderate-to-severe Sj&ouml;gren&#8217;s disease (SjD). This follows the Breakthrough Therapy designation (BTD) received for the same therapy late last year. Presently, there are no advanced treatments approved specifically for this condition.<\/p>\n<\/li>\n<li>\n<p>In 2025, the Sj&ouml;gren&#8217;s disease market size in the US was nearly USD 700 million. This figure is expected to grow significantly with the introduction of emerging therapies.<\/p>\n<\/li>\n<li>\n<p>The total market size of EU4 and the UK was estimated to approximately USD 300 million in 2025.<\/p>\n<\/li>\n<li>\n<p>Among EU4 and the UK, Germany accounted for the highest market share with approximately USD 150 million in 2025, followed by the UK with approximately USD 60 million in the respective year, and France capturing the least market with nearly USD 10 million in 2025.<\/p>\n<\/li>\n<li>\n<p>In 2025, the total market size of Sj&ouml;gren&#8217;s disease was more than USD 30 million in Japan, which is anticipated to increase during the forecast period (2026&ndash;2036).<\/p>\n<\/li>\n<li>\n<p>In the US, total diagnosed prevalent cases of Sj&ouml;gren&rsquo;s disease were approximately 730,000 in 2025, supported by improved recognition of patients presenting with persistent sicca symptoms and the increasing adoption of serological testing, which facilitates disease identification and diagnosis.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight analysis, gender-specific diagnosed prevalent cases of Sj&ouml;gren&rsquo;s disease in the US in 2025 were predominantly female, accounting for more than 650,000 cases, compared with around 75,000 male cases, reflecting the disease&rsquo;s established female predominance.<\/p>\n<\/li>\n<li>\n<p>In 2025, Anti-Ro\/SSA-positive cases represented the largest antibody-specific segment of diagnosed prevalent Sj&ouml;gren&rsquo;s disease cases across EU4 and the UK, totaling to approximately 410,000 cases, followed by Anti-La\/SSB-positive cases at around 290,000.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight analysis, Japan recorded approximately 120,000 diagnosed prevalent cases of Sj&ouml;gren&rsquo;s disease in 2025, of which nearly 82,000 were mild cases, while around 35,000 were moderate-to-severe cases, indicating a substantial diagnosed patient pool with varying disease severity.<\/p>\n<\/li>\n<li>\n<p><strong>Key Sjogren&rsquo;s syndrome Companies:<\/strong> Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherapeutics, Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson &amp; Johnson, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Sjogren&rsquo;s syndrome Therapies:<\/strong> ASP5502, IMVT-1402, Allogeneic, R-2487, BMS-986325, RSLV-132, CFZ533, VIB4920, VAY736, Dazodalibep (VIB4920), OXERVATE (cenegermin), Tivanisiran (SYL1001), Lusvertikimab (formerly OSE-127), Nipocalimab, and others<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Sjogren&rsquo;s syndrome Overview<\/strong><\/p>\n<p style=\"text-align: justify\">Sjogren&rsquo;s Syndrome is a chronic autoimmune disorder in which the body&rsquo;s immune system attacks its own moisture-producing glands, primarily affecting the salivary and tear glands. This leads to persistent dry mouth and dry eyes, and it can also cause fatigue, joint pain, and involvement of other organs such as the kidneys, lungs, or nervous system. Sjogren&rsquo;s syndrome can occur alone (primary) or alongside other autoimmune diseases like rheumatoid arthritis or lupus (secondary). While there is no cure, treatment focuses on relieving symptoms, preventing complications, and managing systemic manifestations.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>To Know in detail about the Sjogren&rsquo;s syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sjogrens-syndrome-market-size?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Sjogren&rsquo;s syndrome Market Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Sjogren&rsquo;s Syndrome Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify\">The Sjogren&rsquo;s Syndrome epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Sjogren&rsquo;s syndrome Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify\">The Sjogren&rsquo;s syndrome market report proffers epidemiological analysis for the study period 2022&ndash;2036 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Diagnosed Prevalent Cases of Sj&ouml;gren&rsquo;s Disease<\/p>\n<\/li>\n<li>\n<p>Type-specific Diagnosed Prevalent Cases of Sj&ouml;gren&rsquo;s Disease<\/p>\n<\/li>\n<li>\n<p>Gender-specific Cases of Sj&ouml;gren&rsquo;s Disease<\/p>\n<\/li>\n<li>\n<p>Antibody-specific Cases of Sj&ouml;gren&rsquo;s Disease<\/p>\n<\/li>\n<li>\n<p>Severity Specific Distribution (ESSDAI Score)<\/p>\n<\/li>\n<li>\n<p>Treated Cases of Sj&ouml;gren&rsquo;s Disease<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Download the report to understand which factors are driving Sjogren&rsquo;s syndrome epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sjogrens-syndrome-market-size?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Sjogren&rsquo;s syndrome Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Sjogren&rsquo;s syndrome Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sjogren&rsquo;s syndrome market or expected to get launched during the study period. The analysis covers Sjogren&rsquo;s syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify\">The report also covers the Sjogren&rsquo;s syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Sjogren&rsquo;s syndrome Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Ianalumab (VAY736): Novartis<\/p>\n<\/li>\n<li>\n<p>Nipocalimab (IMAAVY): Johnson &amp; Johnson<\/p>\n<\/li>\n<li>\n<p>ASP5502: Astellas Pharma Inc<\/p>\n<\/li>\n<li>\n<p>IMVT-1402: Immunovant Sciences<\/p>\n<\/li>\n<li>\n<p>Allogeneic: NK Cells Artiva Biotherapeutics<\/p>\n<\/li>\n<li>\n<p>R-2487: Rise Therapeutics<\/p>\n<\/li>\n<li>\n<p>BMS-986325: Bristol-Myers Squibb<\/p>\n<\/li>\n<li>\n<p>RSLV-132: Resolve Therapeutics<\/p>\n<\/li>\n<li>\n<p>CFZ533: Novartis<\/p>\n<\/li>\n<li>\n<p>VIB4920: Horizon Therapeutics<\/p>\n<\/li>\n<li>\n<p>VAY736: Novartis<\/p>\n<\/li>\n<li>\n<p>Dazodalibep (VIB4920): Horizon Therapeutics (Amgen)<\/p>\n<\/li>\n<li>\n<p>OXERVATE (cenegermin): Dompe Farmaceutici<\/p>\n<\/li>\n<li>\n<p>Tivanisiran (SYL1001): Sylentis<\/p>\n<\/li>\n<li>\n<p>Lusvertikimab (formerly OSE-127): OSE Immunotherapeutics\/Servier<\/p>\n<\/li>\n<li>\n<p>Nipocalimab: Johnson &amp; Johnson<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>To know more about Sjogren&rsquo;s syndrome treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sjogrens-syndrome-market-size?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Sjogren&rsquo;s syndrome Medications<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Sjogren&rsquo;s syndrome Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Rising Prevalence of Autoimmune Disorders: Increasing cases of Sj&ouml;gren&rsquo;s syndrome globally, particularly among women, drive demand for therapies.<\/p>\n<\/li>\n<li>\n<p>Advancements in Targeted Biologics: Development of B-cell targeted therapies, JAK inhibitors, and other immunomodulatory drugs improves treatment outcomes.<\/p>\n<\/li>\n<li>\n<p>Growing Awareness and Early Diagnosis: Enhanced awareness among physicians and patients facilitates timely treatment initiation.<\/p>\n<\/li>\n<li>\n<p>Expansion of Clinical Trials: Rising global R&amp;D activity accelerates the development of novel therapies.<\/p>\n<\/li>\n<li>\n<p>Shift Toward Personalized Medicine: Biomarker-driven and patient-specific treatment approaches enhance therapeutic effectiveness.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Sjogren&rsquo;s syndrome Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Limited Approved Therapies: Few disease-modifying treatments are currently approved, restricting treatment options.<\/p>\n<\/li>\n<li>\n<p>High Treatment Costs: Biologics and advanced therapies are expensive, limiting patient access.<\/p>\n<\/li>\n<li>\n<p>Diagnostic Challenges: Non-specific symptoms and slow disease progression can delay diagnosis.<\/p>\n<\/li>\n<li>\n<p>Variability in Patient Response: Heterogeneous disease manifestations make treatment standardization difficult.<\/p>\n<\/li>\n<li>\n<p>Regulatory and Reimbursement Hurdles: Complex approval processes and limited insurance coverage may hinder market expansion.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Scope of the Sjogren&rsquo;s syndrome Market Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>Study Period: 2022&ndash;2036<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Sjogren&rsquo;s syndrome Companies:<\/strong> Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherapeutics, Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson &amp; Johnson, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Sjogren&rsquo;s syndrome Therapies:<\/strong> ASP5502, IMVT-1402, Allogeneic, R-2487, BMS-986325, RSLV-132, CFZ533, VIB4920, VAY736, Dazodalibep (VIB4920), OXERVATE (cenegermin), Tivanisiran (SYL1001), Lusvertikimab (formerly OSE-127), Nipocalimab, and others<\/p>\n<\/li>\n<li>\n<p><strong>Sjogren&rsquo;s syndrome Therapeutic Assessment:<\/strong> Sjogren&rsquo;s syndrome current marketed and Sjogren&rsquo;s syndrome emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Sjogren&rsquo;s syndrome Market Dynamics:<\/strong> Sjogren&rsquo;s syndrome market drivers and Sjogren&rsquo;s syndrome market barriers<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Sjogren&rsquo;s syndrome Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Sjogren&rsquo;s syndrome Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Discover more about therapies set to grab major Sjogren&rsquo;s syndrome market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sjogrens-syndrome-market-size?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Sjogren&rsquo;s syndrome Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify\">1. Sjogren&rsquo;s syndrome Market Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Executive Summary for Sjogren&rsquo;s syndrome<\/p>\n<p style=\"text-align: justify\">3. SWOT analysis of Sjogren&rsquo;s syndrome<\/p>\n<p style=\"text-align: justify\">4. Sjogren&rsquo;s syndrome Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify\">5. Sjogren&rsquo;s syndrome Market Overview at a Glance<\/p>\n<p style=\"text-align: justify\">6. Sjogren&rsquo;s syndrome Disease Background and Overview<\/p>\n<p style=\"text-align: justify\">7. Sjogren&rsquo;s syndrome Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify\">8. Country-Specific Patient Population of Sjogren&rsquo;s syndrome<\/p>\n<p style=\"text-align: justify\">9. Sjogren&rsquo;s syndrome Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify\">10. Sjogren&rsquo;s syndrome Unmet Needs<\/p>\n<p style=\"text-align: justify\">11. Sjogren&rsquo;s syndrome Emerging Therapies<\/p>\n<p style=\"text-align: justify\">12. Sjogren&rsquo;s syndrome Market Outlook<\/p>\n<p style=\"text-align: justify\">13. Country-Wise Sjogren&rsquo;s syndrome Market Analysis (2022&ndash;2036)<\/p>\n<p style=\"text-align: justify\">14. Sjogren&rsquo;s syndrome Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify\">15. Sjogren&rsquo;s syndrome Market drivers<\/p>\n<p style=\"text-align: justify\">16. Sjogren&rsquo;s syndrome Market barriers<\/p>\n<p style=\"text-align: justify\">17. Sjogren&rsquo;s syndrome Appendix<\/p>\n<p style=\"text-align: justify\">18. Sjogren&rsquo;s syndrome Report Methodology<\/p>\n<p style=\"text-align: justify\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify\">20. Disclaimer<\/p>\n<p style=\"text-align: justify\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=sjogrens-syndrome-market-poised-for-sustained-growth-amid-advancements-in-treatment-and-clinical-innovation-by-2036-delveinsight-astellas-pharma-immunovant-sciences-nk-cells-artiva-biotherap\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=sjogrens-syndrome-market-poised-for-sustained-growth-amid-advancements-in-treatment-and-clinical-innovation-by-2036-delveinsight-astellas-pharma-immunovant-sciences-nk-cells-artiva-biotherap\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Sjogren\u2019s syndrome Companies in the market include &#8211; Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherapeutics, Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/552885"}],"collection":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/comments?post=552885"}],"version-history":[{"count":0,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/552885\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/media?parent=552885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/categories?post=552885"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/tags?post=552885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}